Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: A systematic review

Pan African Medical Journal

Volumn 15, Issue , 2013, Pages

  Vouking, Marius Zambou ^a   Tamo, Violette Claire ^a   Tadenfok, Carine Nouboudem ^b  

^a YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

^b Burundi   (Cameroon)

Author keywords

Antibiotics treatment; Clinical efficacy; Mycobacterium ulcerans infection; Rifampicin; Streptomycin

Indexed keywords

RIFAMPICIN; STREPTOMYCIN;

AMPUTATION; BACTERIUM CULTURE; BURULI ULCER; COST OF ILLNESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; FOLLOW UP; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; INJECTION SITE ABSCESS; LENGTH OF STAY; MYCOBACTERIUM ULCERANS; POLYMERASE CHAIN REACTION; RELAPSE; REVIEW; SKIN SURGERY; SURGICAL DRAINAGE; SYSTEMATIC REVIEW; TREATMENT DURATION; ULCER HEALING; ANTIBIOTICS TREATMENT; ATYPICAL MYCOBACTERIOSIS; CLINICAL EFFICACY; DRUG COMBINATION; DRUG EFFECT; HOSPITALIZATION; ORAL DRUG ADMINISTRATION; STATISTICS; SURGERY; TREATMENT OUTCOME;

ANTIBIOTICS TREATMENT; CLINICAL EFFICACY; MYCOBACTERIUM ULCERANS INFECTION; RIFAMPICIN; STREPTOMYCIN;

ADMINISTRATION, ORAL; DRUG THERAPY, COMBINATION; HOSPITALIZATION; HUMANS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 84887440720     PISSN: 19378688     EISSN: None     Source Type: Journal    
DOI: 10.11604/pamj.2013.15.155.2341     Document Type: Review

References (23)

1. WHO. Global Experience of Community Health Workers for Delivery of Health Related Millennium Development Goals: A Systematic Review, Country Case Studies, and Recommendations for Integration into National Health Systems. 2010. Geneva. WHO. PubMed | Google Scholar
2. Wansbrough-Jones M, Phillips R. Buruli ulcer: emerging from obscurity. Lancet. 2006; 367(9525): 1849-1858. PubMed| Google Scholar
3. Stienstra Y, van Roest MH, van Wezel MJ, et al. Factors associated with functional limitations and subsequent employment or schooling in Buruli ulcer patients. Trop Med Int Health. 2005; 10(12): 1251-1257. PubMed | Google Scholar
4. Van der Werf TS, Stinear T, Stienstra Y, van der Graaf WTA, Small PL. Mycolactones and Mycobacterium ulcerans disease. Lancet. 2003; 362(9389): 1062-1064. PubMed | Google Scholar
5. Havel A, and Pattyn SR. Activity of Rifampicin on Mycobacterium ulcerans. Ann. Soc. Belg. Med. Trop. 1975; 55(2):105-108. PubMed | Google Scholar
6. Portaels F, Traore H. De Ridder K, Meyers WM. In vitro susceptibility of Mycobacterium ulcerans to Clarithromycin. Antimicrob Agents Chemother. 1998; 42(8):2070-2073. PubMed | Google Scholar
7. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination Rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother. 2005; 49(8): 3182-3186. PubMed | Google Scholar
8. WHO. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). 2005. Geneva, Switzerland. World Health Organization. PubMed | Google Scholar
9. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, Tuah W, Awua-Boateng NY, Ampadu EO, Siegmund V, Schouten JP, Adjei O, Bretzel G, van der Werf TS. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomized controlled trial. Lancet. 2010 Feb 20;375(9715):664-72. PubMed | Google Scholar
10. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JAM, et al. All-Oral Antibiotic Treatment for Buruli Ulcer: A Report of Four Patients. PLoS Negl Trop Dis. 2010; 4(11): e770. PubMed | Google Scholar
11. O'Brien DP, McDonald A, Callan P, Robson M, Friedman ND, et al. Successful Outcomes with Oral Fluoroquinolones Combined with Rifampicin in the Treatment of Mycobacterium ulcerans: An Observational Cohort Study. PLoS Negl Trop Dis. 2012; 6(1): e1473. doi:10.1371/journal.pntd.0001473. PubMed | Google Scholar
12. Saka B, Landoh DE, Kobara B, Djadou KE, Yaya I, Yékplé KB, Piten E, Balaka A, Akakpo S, Kombaté K, Mouhari-Toure A, Kanassoua K, Pitché P. Profile of Buruli ulcer treated at the National Reference Centre of Togo: a study of 119 cases. Bull Soc Pathol Exot. 2013 Feb;106(1):32-6. PubMed | Google Scholar
13. Chauty A, Ardant MF, Adeye A, Euverte H, Guédénon A, Johnson C, Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis. 2011. 5(1): e933. PubMed | Google Scholar
14. Kibadi K, Boelaert M, Fraga AG, Kayinua M, Longatto-Filho A, et al. Response to Treatment in a Prospective Cohort of Patients with Large Ulcerated Lesions Suspected to Be Buruli Ulcer (Mycobacterium ulcerans Disease). PLoS Negl Trop Dis. 2010; 4(7): e736. PubMed | Google Scholar
15. Agbenorku P, Agbenorku M, Gotah E, Saundersonand P, Lehman L. Benefits of a combination of surgery and chemotherapy in the management of Buruli the ulcer patients. J Sci Tech. 2006;26(2):6-21. PubMed | Google Scholar
16. Alffenaar JWC, Nienhuis WA, de Velde F, Zuur AT. Wessels AMA, Almeida D, Grosset J, Adjei O, Uges DRA, van der Werf TS. Pharmacokinetics of Rifampin and Clarithromycin in Patients Treated for Mycobacterium ulcerans Infection. Antimicrobial Agents and Chemotherapy. Sept 2010; 54(9): 3878-3883. PubMed | Google Scholar
17. Ji B, Chauffour A, Robert J, Lefrançois S, Jarlier V. Orally administred combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrobial agents and chemotherapy. Oct 2007;51(10): p. 3737-3739. PubMed | Google Scholar
18. Ji B, Chauffour A, Aubry A, Robert J, Ibrahim I, Jarlier V. Impacts of Dosing Frequency of the Combination Rifampin-Streptomycin on Its Bactericidal and Sterilizing Activities against Mycobacterium ulcerans in Mice. Antimicrobial agents and chemotherapy. July 2009; 53(7): 2955-2959. PubMed | Google Scholar
19. Chauty A, Ardant MF, Adeye A, et al. Promising clinical efficacy of Streptomycin-Rifampin combination for treatment of Buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother. 2007; 51(11): 4029-4035. PubMed |Google Scholar
20. Van der Werf TS, Stienstra Y, Johnson RC, et al. Mycobacterium ulcerans disease. Bull World Health Organ. 2005; 83(10): 785-791. PubMed | Google Scholar
21. Dega HA, Bentoucha J, Robert V, Jarlier and Grosset J. Bactericidal activity of Rifampin-Amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother. 2002; 46(10):3193-3196. PubMed | Google Scholar
22. Buntine JC, Etuaful S, Johnson C, Grosset J, Portaels F, Wansbrough-Jones M. Recommandations provisoires pour certains antibiotiques dans la prise en charge de l?infection à Mycobacterium ulcerans (ulcère de Buruli). 2004. Geneva. WHO (Organisation Mondiale de la Santé). PubMed | Google Scholar
23. Almeida D, Converse PJ, Ahmad Z, Dooley KE, Nuermberger EL, et al. Activities of Rifampin, Rifapentine and Clarithromycin Alone and in Combination against Mycobacterium ulcerans Disease in Mice. PLoS Negl Trop Dis.2011; 5(1): 933. PubMed | Google Scholar